Accession | Title | Series type(s) | Organism(s) | Samples | GDS | Supplementary | Contact | Release date |
---|---|---|---|---|---|---|---|---|
![]() |
![]() |
|||||||
GSE216987 |
Decitabine treatment reveals a functional role of DNA hypomethylation in organising enhancer-promoter interactions [Promoter Capture Hi-C]
|
8 | Joanna Achinger-Kawecka | Aug 08, 2023 | ||||
GSE216988 |
Decitabine treatment reveals a functional role of DNA hypomethylation in organising enhancer-promoter interactions [RNA-seq]
|
8 | Joanna Achinger-Kawecka | Aug 08, 2023 | ||||
GSE216986 |
Decitabine treatment reveals a functional role of DNA hypomethylation in organising enhancer-promoter interactions [EPIC]
|
8 | Joanna Achinger-Kawecka | Aug 07, 2023 | ||||
GSE216989 |
Decitabine treatment reveals a functional role of DNA hypomethylation in organising enhancer-promoter interactions
|
24 | Joanna Achinger-Kawecka | Aug 07, 2023 | ||||
GSE237768 |
Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer [WGBS]
|
8 | Joanna Achinger-Kawecka | Jul 24, 2023 | ||||
GSE237769 |
Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer [CUT&RUN]
|
13 | Joanna Achinger-Kawecka | Jul 24, 2023 | ||||
GSE171066 |
Epigenetic therapy suppresses tumour growth by rewiring ER-mediated long-range chromatin interactions in ER+ endocrine-resistant breast cancer [methylation GAR15-13]
|
8 | Joanna Achinger-Kawecka | Dec 12, 2021 | ||||
GSE171069 |
Epigenetic therapy suppresses tumour growth by rewiring ER-mediated long-range chromatin interactions in ER+ endocrine-resistant breast cancer [methylation HCI-005]
|
8 | Joanna Achinger-Kawecka | Dec 12, 2021 | ||||
GSE171070 |
Epigenetic therapy suppresses tumour growth by rewiring ER-mediated long-range chromatin interactions in ER+ endocrine-resistant breast cancer [ChIP-seq]
|
23 | Joanna Achinger-Kawecka | Dec 12, 2021 | ||||
GSE171071 |
Epigenetic therapy suppresses tumour growth by rewiring ER-mediated long-range chromatin interactions in ER+ endocrine-resistant breast cancer [HiC]
|
6 | Joanna Achinger-Kawecka | Dec 12, 2021 | ||||
GSE171072 |
Epigenetic therapy suppresses tumour growth by rewiring ER-mediated long-range chromatin interactions in ER+ endocrine-resistant breast cancer [PCHiC]
|
6 | Joanna Achinger-Kawecka | Dec 12, 2021 | ||||
GSE171073 |
Epigenetic therapy suppresses tumour growth by rewiring ER-mediated long-range chromatin interactions in ER+ endocrine-resistant breast cancer [RNA-seq]
|
16 | Joanna Achinger-Kawecka | Dec 12, 2021 | ||||
GSE171074 |
The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer
|
88 | Joanna Achinger-Kawecka | Dec 12, 2021 | ||||
GSE150252 |
BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer
|
12 | Joanna Achinger-Kawecka | Feb 10, 2021 | ||||
GSE118711 |
Epigenetic reprogramming at estrogen-receptor binding sites alters the 3D chromatin landscape in endocrine resistant breast cancer [ChIP-seq]
|
14 | Joanna Achinger-Kawecka | Dec 11, 2019 | ||||
GSE118712 |
Epigenetic reprogramming at estrogen-receptor binding sites alters the 3D chromatin landscape in endocrine resistant breast cancer [Hi-C]
|
9 | Joanna Achinger-Kawecka | Dec 11, 2019 | ||||
GSE118713 |
Epigenetic reprogramming at estrogen-receptor binding sites alters the 3D chromatin landscape in endocrine resistant breast cancer [RNA-seq]
|
9 | Joanna Achinger-Kawecka | Dec 11, 2019 | ||||
GSE118714 |
Epigenetic reprogramming at estrogen-receptor binding sites alters the 3D chromatin landscape in endocrine resistant breast cancer [WGBS]
|
3 | Joanna Achinger-Kawecka | Dec 11, 2019 | ||||
GSE118715 |
Epigenetic reprogramming at estrogen-receptor binding sites alters the 3D chromatin landscape in endocrine resistant breast cancer [WGS]
|
5 | Joanna Achinger-Kawecka | Dec 11, 2019 | ||||
GSE118716 |
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine resistant breast cancer
|
40 | Joanna Achinger-Kawecka | Dec 11, 2019 |